Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals (ALNY) PT Raised to $202 at Cantor Fitzgerald Following Announced Blackstone Deal
April 14, 2020 7:03 AM EDTCantor Fitzgerald analyst Alethia Young raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $202.00 (from $195.00) while maintaining a Overweight rating following the Blackstone (NYSE: BX) deal announced on April 13th. The deal is centered around the inclisiran royalty. Investor... More
